KDC-MN-046 – Kodiac biolabs

Plain-language summaryIntrigue 75 / 100

Donepezil, sold as Aricept, is the most prescribed acetylcholinesterase inhibitor for Alzheimer disease. It selectively raises brain acetylcholine to compensate for cholinergic neuron loss in dementia. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

47/100

Mature gold-standard AChE inhibitor with unmatched clinical data but negligible research novelty

Look, donepezil is the reference standard for its entire drug class and thats not nothing. Thirty years of clinical data, FDA approval across three dementia subtypes, better pharmacokinetics than anything else in the AChE inhibitor family. If you’re building a research program around cholinergic pharmacology, donepezil is the tool you reach for to establish a benchmark. That’s genuine bench value and we’re crediting it.

Here’s the thing though: the mechanism is a single, thoroughly characterized enzyme inhibition. Acetylcholinesterase is not a frontier target. The cholinergic hypothesis of Alzheimer disease has been researched continuously since the early 1980s, and donepezil is its most refined expression. The greater-than-1000-fold selectivity over butyrylcholinesterase is impressive engineering, but it doesn’t add new pharmacology. You get more ACh at the synapse. That’s it. The compound has essentially no significant secondary receptor activities at therapeutic concentrations, and the clean profile that makes it clinically useful is the same thing that makes it mechanistically uninteresting.

The clinical picture reinforces the research picture. Multiple Phase 3 RCTs confirm real, consistent effects on ADAS-cog and MMSE in Alzheimer populations. The effects are small, symptomatic, and non-disease-modifying. The field’s attention has largely moved toward amyloid-directed biologics, tau pathology, and neuroinflammation. Donepezil sits on the approved-drug shelf while the genuinely interesting work happens elsewhere.

There are niche angles that keep donepezil relevant as a tool: some groups are probing sigma-1 receptor co-pharmacology, and the cognitive-enhancement literature in healthy subjects occasionally runs donepezil as a comparator or probe. Recent interest in Lewy body dementia and sleep architecture represents maybe the most active current fringe. None of those are sufficient to move the novelty needle in a meaningful way.

What we like: the pharmacokinetics are genuinely excellent for a research setting. Once-daily oral dosing, essentially complete bioavailability, clean hepatic metabolism via CYP2D6 and CYP3A4. If you need a cholinergic reference compound, donepezil is the professional choice. What we don’t like for a research library context: you’re not going to answer a new question with it. The mechanism is characterized, the population response is characterized, and the ceiling on what AChE inhibition can do in humans has been fairly well defined by decades of modest-but-real phase 3 results.

Overall, donepezil earns its place as a serious reference tool, and the evidence base is one of the strongest in this library. But it’s not a frontier compound. This is mature, proven cholinergic pharmacology, and the score reflects that honestly.

Novelty: 20
Mechanism promise: 28
In-category differentiation: 50
Evidence quality: 82
Translational signal: 68
Research bench value: 50

Rationale Donepezil leads its class on selectivity and evidence depth, but the mechanism is a single well-characterized enzyme inhibition exhaustively studied for three decades; high evidence and translational scores are offset by minimal novelty and mechanism promise, placing this squarely in the mature-but-uninspiring tier.

Selective acetylcholinesterase inhibitor

A piperidine-class selective reversible acetylcholinesterase inhibitor, FDA-approved as Aricept for Alzheimer disease, with the largest clinical evidence base of the AChE inhibitor class.

Abstract

Donepezil (Aricept; (R/S)-2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one hydrochloride; CAS 120014-06-4; molecular formula C24H29NO3; molecular weight 379.49) is a piperidine-class selective reversible acetylcholinesterase inhibitor developed by Eisai and approved by the FDA in 1996 for mild, moderate, and severe Alzheimer disease. The compound has the highest AChE selectivity (over 1000-fold versus butyrylcholinesterase) of the marketed AChE inhibitors and a long plasma half-life (70 hours) that supports once-daily dosing. Mechanism is selective AChE inhibition without significant secondary activities at nicotinic receptors or other targets. The clinical evidence base in Alzheimer disease is extensive; multiple Phase 3 trials demonstrate small but consistent improvements in cognitive endpoint measures (ADAS-cog, MMSE) and global functional status. The compound is also approved for vascular dementia and Parkinson disease dementia in some jurisdictions. Pharmacokinetics: oral bioavailability essentially complete; metabolism is hepatic via CYP2D6 and CYP3A4 with minor active metabolites. Approved doses are 5 to 23 mg per day; the 23 mg formulation was approved in 2010 for severe Alzheimer disease. Schedule status: prescription-only but not federally scheduled.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-046Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-046

Donepezil

Abstract

Read the full monograph